These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels. Novakovic V, Abdija S, Larsen PB, Fenger M, Gredal L, Jacobsen KK. Clin Biochem; 2019 Dec 15; 74():73-75. PubMed ID: 31669514 [Abstract] [Full Text] [Related]
15. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Inflamm Bowel Dis; 2010 Nov 15; 16(11):1898-904. PubMed ID: 20310016 [Abstract] [Full Text] [Related]
16. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B. J Pediatr Gastroenterol Nutr; 2018 Oct 15; 67(4):507-512. PubMed ID: 29901557 [Abstract] [Full Text] [Related]
19. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease. Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF. Clinics (Sao Paulo); 2019 Apr 08; 74():e824. PubMed ID: 30994711 [Abstract] [Full Text] [Related]
20. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G. J Pediatr Gastroenterol Nutr; 2019 Oct 08; 69(4):474-479. PubMed ID: 31149938 [Abstract] [Full Text] [Related] Page: [Next] [New Search]